Edition:
India

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

3.11USD
17 Nov 2017
Change (% chg)

$0.05 (+1.63%)
Prev Close
$3.06
Open
$3.07
Day's High
$3.15
Day's Low
$3.00
Volume
298,759
Avg. Vol
563,696
52-wk High
$4.24
52-wk Low
$0.50

Select another date:

Tue, Nov 7 2017

BRIEF-AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22

* AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification

* Aveo Pharmaceuticals Inc - ‍announces completion of Tivo-3 study futility analysis with no changes to study protocol​

BRIEF-AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-in

* Aveo Pharmaceuticals Inc - ‍EUSA Pharma has agreed to pay AVEO up to $388 million in future milestone payments and research and development funding​

BRIEF-Aveo Oncology announces Fotivda approved in the EU for the treatment of advanced renal cell carcinoma

* Aveo Oncology announces Fotivda® (tivozanib) approved in the European Union for the treatment of advanced renal cell carcinoma

BRIEF-Aveo Pharmaceuticals Inc Q2 loss per share $0.30

* Aveo reports second quarter 2017 financial results and provides business update

BRIEF-Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings

* Aveo Oncology announces $14m in aggregate gross proceeds from Hercules Credit Facility and at-the-market stock offerings

EU regulators greenlight U.S. biotech Aveo's kidney cancer drug

European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market.

UPDATE 1-EU regulators greenlight U.S. biotech Aveo's kidney cancer drug

June 23 European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market.

BRIEF-Aveo Oncology announces phase 1/2 tinivo trial

* Aveo Oncology announces phase 1/2 tinivo trial of tivozanib and opdivo® (nivolumab) in RCC advances to phase 2

Select another date: